AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
The following information and Exhibit99.1 and Exhibit99.2 attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) except as expressly set forth by specific reference in such filing.
On August 3, 2017, AMAG Pharmaceuticals, Inc. (“AMAG”) issued a press release entitled “AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update” regarding its operating results for the quarter and six months ended June 30, 2017 and its intention to hold a conference call to discuss AMAG’s financial and operating results and recent business highlights. A copy of AMAG’s press release is furnished herewith as Exhibit99.1 and a copy of the presentation slides to be used during the conference call is furnished herewith as Exhibit99.2.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
AMAG hereby furnishes the following exhibits:
|
Exhibit Number |
Description |
|
99.1 |
Press release entitled “AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update” issued by AMAG Pharmaceuticals,Inc. on August 3, 2017. |
|
99.2 |
Copy of AMAG Pharmaceuticals, Inc.’s presentation slides dated August 3,2017. |
AMAG PHARMACEUTICALS INC. ExhibitEX-99.1 2 ex991q22017earningsrelease.htm EXHIBIT 99.1 Exhibit FOR IMMEDIATE RELEASEAMAG PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATESecond quarter 2017 GAAP revenue increased 24% over same period last yearIntrarosaTM (prasterone) now commercially availableCompleted Feraheme® (ferumoxytol) submission to FDA to broaden label beyond chronic kidney disease Conference call scheduled for 8:00 a.m. ET todayWALTHAM,…To view the full exhibit click here
About AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG)
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
